Efficacy of the Anti-Candida rAls3p-N or rAls1p-N Vaccines against Disseminated and Mucosal Candidiasis.
Spellberg, Brad J. 1,2; Ibrahim, Ashraf S. 1,2; Avanesian, Valentina 1; Fu, Yue 1,2; Myers, Carter 1; Phan, Quynh T. 1; Filler, Scott G. 1,2; Yeaman, Michael R. Jr 1,2; Edwards, John E. 1,2
[Report] Journal of Infectious Diseases. 194(2):256-260, July 15, 2006.

(Format: HTML, PDF)

: We have shown that vaccination with the recombinant N terminus of Als1p (rAls1p-N) protects mice against disseminated and oropharyngeal candidiasis. We now report that vaccination of mice with a related candidate, rAls3p-N, induces a broader antibody response than rAls1p-N and a similar cell-mediated immune response. The rAls3p-N vaccine was equally as effective as rAls1p-N against disseminated candidiasis but was more effective than rAls1p-N against oropharyngeal or vaginal candidiasis. Antibody titers did not correlate with protection against disseminated candidiasis, but delayed-type hypersensitivity did. The rAls3p-N vaccine is a promising new vaccine candidate for further exploration to prevent systemic and mucosal candidal infections

(C) Copyright Oxford University Press 2006.